samatasvir + omeprazole

Samatasvir + omeprazole is an investigational drug combination consisting of samatasvir, a hepatitis C virus (HCV) non-structural protein 5A (NS5A) inhibitor, and omeprazole, a proton pump inhibitor (PPI) commonly used to reduce gastric acid secretion. Samatasvir acts by inhibiting the replication of HCV through targeting the NS5A protein, a key regulator in the hepatitis C viral life cycle[2][6][10]. Omeprazole decreases stomach acid to manage gastrointestinal symptoms and, in this context, is generally studied for potential drug-drug interactions with samatasvir given its effect on gastric pH, which can impact the absorption of some antiviral agents[2][10]. Clinical studies have assessed the safety, pharmacokinetics, and possible interactions between these two drugs, particularly focusing on whether omeprazole affects the absorption or efficacy of samatasvir[2][10].

Brand names

PriLOSECPriLOSEC OTCFIRST OmeprazoleZegerid